500 related articles for article (PubMed ID: 29933399)
21. Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates.
Saunders KO; Nicely NI; Wiehe K; Bonsignori M; Meyerhoff RR; Parks R; Walkowicz WE; Aussedat B; Wu NR; Cai F; Vohra Y; Park PK; Eaton A; Go EP; Sutherland LL; Scearce RM; Barouch DH; Zhang R; Von Holle T; Overman RG; Anasti K; Sanders RW; Moody MA; Kepler TB; Korber B; Desaire H; Santra S; Letvin NL; Nabel GJ; Montefiori DC; Tomaras GD; Liao HX; Alam SM; Danishefsky SJ; Haynes BF
Cell Rep; 2017 Feb; 18(9):2175-2188. PubMed ID: 28249163
[TBL] [Abstract][Full Text] [Related]
22. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.
Wibmer CK; Gorman J; Anthony CS; Mkhize NN; Druz A; York T; Schmidt SD; Labuschagne P; Louder MK; Bailer RT; Abdool Karim SS; Mascola JR; Williamson C; Moore PL; Kwong PD; Morris L
J Virol; 2016 Nov; 90(22):10220-10235. PubMed ID: 27581986
[TBL] [Abstract][Full Text] [Related]
23. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.
Schoofs T; Barnes CO; Suh-Toma N; Golijanin J; Schommers P; Gruell H; West AP; Bach F; Lee YE; Nogueira L; Georgiev IS; Bailer RT; Czartoski J; Mascola JR; Seaman MS; McElrath MJ; Doria-Rose NA; Klein F; Nussenzweig MC; Bjorkman PJ
Immunity; 2019 Jun; 50(6):1513-1529.e9. PubMed ID: 31126879
[TBL] [Abstract][Full Text] [Related]
24. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
[TBL] [Abstract][Full Text] [Related]
25. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.
McGuire AT; Hoot S; Dreyer AM; Lippy A; Stuart A; Cohen KW; Jardine J; Menis S; Scheid JF; West AP; Schief WR; Stamatatos L
J Exp Med; 2013 Apr; 210(4):655-63. PubMed ID: 23530120
[TBL] [Abstract][Full Text] [Related]
26. Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization.
Parks KR; MacCamy AJ; Trichka J; Gray M; Weidle C; Borst AJ; Khechaduri A; Takushi B; Agrawal P; Guenaga J; Wyatt RT; Coler R; Seaman M; LaBranche C; Montefiori DC; Veesler D; Pancera M; McGuire A; Stamatatos L
Cell Rep; 2019 Dec; 29(10):3060-3072.e7. PubMed ID: 31801073
[TBL] [Abstract][Full Text] [Related]
27. Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies.
Kesavardhana S; Das R; Citron M; Datta R; Ecto L; Srilatha NS; DiStefano D; Swoyer R; Joyce JG; Dutta S; LaBranche CC; Montefiori DC; Flynn JA; Varadarajan R
J Biol Chem; 2017 Jan; 292(1):278-291. PubMed ID: 27879316
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.
Kwong PD; Mascola JR
Immunity; 2018 May; 48(5):855-871. PubMed ID: 29768174
[TBL] [Abstract][Full Text] [Related]
29. Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.
Pritchard LK; Harvey DJ; Bonomelli C; Crispin M; Doores KJ
J Virol; 2015 Sep; 89(17):8932-44. PubMed ID: 26085151
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.
Bricault CA; Yusim K; Seaman MS; Yoon H; Theiler J; Giorgi EE; Wagh K; Theiler M; Hraber P; Macke JP; Kreider EF; Learn GH; Hahn BH; Scheid JF; Kovacs JM; Shields JL; Lavine CL; Ghantous F; Rist M; Bayne MG; Neubauer GH; McMahan K; Peng H; Chéneau C; Jones JJ; Zeng J; Ochsenbauer C; Nkolola JP; Stephenson KE; Chen B; Gnanakaran S; Bonsignori M; Williams LD; Haynes BF; Doria-Rose N; Mascola JR; Montefiori DC; Barouch DH; Korber B
Cell Host Microbe; 2019 Jan; 25(1):59-72.e8. PubMed ID: 30629920
[TBL] [Abstract][Full Text] [Related]
31. Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.
Hicar MD; Chen X; Sulli C; Barnes T; Goodman J; Sojar H; Briney B; Willis J; Chukwuma VU; Kalams SA; Doranz BJ; Spearman P; Crowe JE
PLoS One; 2016; 11(7):e0158861. PubMed ID: 27411063
[TBL] [Abstract][Full Text] [Related]
32. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
33. An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.
Shubin Z; Li W; Poonia B; Ferrari G; LaBranche C; Montefiori D; Zhu X; Pauza CD
Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28404572
[TBL] [Abstract][Full Text] [Related]
34. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
35. Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.
Dennis M; Eudailey J; Pollara J; McMillan AS; Cronin KD; Saha PT; Curtis AD; Hudgens MG; Fouda GG; Ferrari G; Alam M; Van Rompay KKA; De Paris K; Permar S; Shen X
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541851
[TBL] [Abstract][Full Text] [Related]
36. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
[TBL] [Abstract][Full Text] [Related]
37. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
[TBL] [Abstract][Full Text] [Related]
38. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
[TBL] [Abstract][Full Text] [Related]
39. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.
Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Derdeyn CA
Front Immunol; 2018; 9():3163. PubMed ID: 30697215
[TBL] [Abstract][Full Text] [Related]
40. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.
Hoot S; McGuire AT; Cohen KW; Strong RK; Hangartner L; Klein F; Diskin R; Scheid JF; Sather DN; Burton DR; Stamatatos L
PLoS Pathog; 2013 Jan; 9(1):e1003106. PubMed ID: 23300456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
